- Home
- DNLI vs IDYA Comparison
DNLI vs IDYA Comparison
Compare DNLI & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DNLI | IDYA |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.9B |
| IPO Year | 2017 | 2019 |
Fundamental Metrics
Financial Performance| Metric | DNLI | IDYA |
|---|---|---|
| Price | $16.99 | $35.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 13 |
| Target Price | $32.58 | ★ $49.18 |
| AVG Volume (30 Days) | ★ 1.7M | 981.7K |
| Earning Date | 11-06-2025 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $214,834,000.00 |
| Revenue This Year | N/A | $2,662.86 |
| Revenue Next Year | $3,973.10 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 5377.66 |
| 52 Week Low | $10.57 | $13.45 |
| 52 Week High | $24.35 | $37.08 |
Technical Indicators
Market Signals| Indicator | DNLI | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 43.95 | 58.54 |
| Support Level | $16.66 | $33.11 |
| Resistance Level | $17.85 | $34.45 |
| Average True Range (ATR) | 0.80 | 1.23 |
| MACD | -0.22 | 0.02 |
| Stochastic Oscillator | 2.69 | 56.66 |
Price Performance
Historical ComparisonAbout DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.